AMEDISYS Inc
AMED
ISIN null / Valor 399513
AMEDISYS Inc
UMushroom community rating:
About company
Amedisys Inc. is a U.S. healthcare company that provides home-based care through a national network of locations, focusing on home health (skilled nursing and rehabilitation therapies), hospice (end-of-life care) and personal-care services. The company contracts with Medicare, Medicaid and commercial insurers under fee-for-service and value-based arrangements, and emphasizes care coordination and technology-enabled management to deliver clinical services and reduce reliance on institutional care. Operating as one of the larger national home health and hospice providers, Amedisys generates revenue from patient services and care-management programs and competes in the expanding post‑acute and home-care market. It is publicly traded on the Nasdaq (AMED).
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (12.01.2026):
AMEDISYS Inc reported results for the second quarter of 2025. Net service revenue rose to $621.9 million (up $30.7 million vs. Q2 2024). GAAP net income attributable to the company was $28.1 million ($0.84 diluted EPS), which included $26.3 million of merger-related expenses. On an adjusted basis, Amedisys reported adjusted EBITDA of $80.8 million and adjusted net income of $51.4 million ($1.54 adjusted diluted EPS). The company did not hold an earnings call because of the pending merger with UnitedHealth Group.
Revenue
Net service revenue for Q2 2025 was $621.9 million, up $30.7 million from $591.2 million in Q2 2024. Year-to-date (six months) net service revenue was $1,216.6 million, up $54.0 million versus the first half of 2024.
GAAP Net Income & EPS
GAAP net income attributable to AMEDISYS Inc for Q2 2025 was $28.1 million (diluted EPS $0.84) versus $32.3 million (diluted EPS $0.98) in Q2 2024. Six-month GAAP net income was $89.1 million (diluted EPS $2.68) versus $46.7 million (diluted EPS $1.42) in the prior year period.
Adjusted Results
Q2 2025 adjusted EBITDA was $80.8 million (vs. $73.2M in Q2 2024). Adjusted net income for the quarter was $51.4 million (adjusted diluted EPS $1.54) versus $43.5 million ($1.32) a year ago. Adjusted YTD EBITDA was $149.6 million and adjusted YTD net income was $93.0 million (adjusted diluted EPS $2.80), both higher than the comparable 2024 periods.
Merger-Related and One-Time Items
Merger-related expenses materially impacted results: $26.3 million in Q2 2025 and $43.0 million year-to-date. The six-month period also included a $48.1 million gain on an equity method investment (reported pre-tax), which helped lift YTD GAAP net income.
Cash Flow, Receivables & Liquidity
Operating cash flow for Q2 2025 was $67.2 million (vs. $52.3M in Q2 2024). Cash, cash equivalents and restricted cash at period end were reported at $337.3 million (June 30, 2025). Days revenue outstanding improved to 40.9 days from 52.1 days in the prior-year quarter.
Corporate & Other Notes
Because of the pending merger with UnitedHealth Group, AMEDISYS Inc did not conduct a quarterly earnings call. The company continues to disclose reconciliations of its non-GAAP measures (adjusted EBITDA and adjusted net income) to GAAP in the release and supplemental slides. Summarized from source with an LLMView Source
Key figures
Performance
Volatility
3321 M
Market cap (USD)
Daily traded volume (Shares)
90.89 / 89.6
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
